Our proprietary Lm-based Antigen Delivery System triggers the patient’s own immune system against tumors. Learn more.
Lm-based Antigen Delivery System
AIM2CERV is the only industry-sponsored phase 3 clinical study focused on cervical cancer in the world. Learn more.
Aiming to Prevent Cervical Cancer Recurrence
Advancing under a clinical development program between Amgen and Advaxis. MINETM has the potential to provide patients with a truly customized approach to cancer treatment by stimulating an immune response against unique mutations, or neoantigens, contained in each patient’s tumor. Learn more.
With the only industry sponsored phase 3 clinical study underway, Advaxis remains committed to supporting the cervical cancer community. Learn more.
Committed to the Cervical Cancer Patient Community